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Abstract
Background: Lower extremity complications (neuropathy, ulceration, infection, and peripheral
arterial disease) are common in diabetes mellitus. There is an inverse relation between plasma
testosterone and insulin sensitivity, type 2 diabetes mellitus and HbA1c concentrations.
Methods: We report the beneficial effects of administration of testosterone to three men with a
diabetic foot whose serum testosterone was subnormal.
Results: Upon normalization of serum testosterone there was an improvement of hyperglycemia,
a decrease of leukocytes and of fibrinogen levels, an increase of antithrombin III activity and of
tissue oxygen pressure. The wound showed granulation.
Conclusion: Beneficial effects of administration of testosterone to hypogonadal with a diabetic
foot may be due to improved vascularization and to anti-inflammatory action.
Background
Lower extremity complications are common in patients
with diabetes and include neuropathy, ulceration, infec-
tion, and peripheral arterial disease. Foot infections repre-
sent the single most common cause of hospitalization and
lower extremity amputation in persons with diabetes.
Foot ulceration as a result of diabetic peripheral sensory
neuropathy, rigid osseous deformities and soft-tissue con-
tractures, repetitive trauma from unprotected ambulation,
and peripheral vascular disease can all lead to a limb- or
even life-threatening infection.
Men with type 2 diabetes have a lower serum testosterone
concentration compared to men without a history of dia-
betes, and there is an inverse association between testo-
sterone levels and HbA1c concentrations[1]. A recent
systematic review and meta-analysis of cross-sectional
studies indicated that testosterone levels were signifi-
cantly lower in men with type 2 diabetes[2]. Further, in
men with low plasma testosterone the risk of diabetes
mellitus is increased[3]. One third to one half of men with
type 2 diabetes mellitus are now recognized as testoster-
one deficient. Emerging evidence suggests that testoster-
one therapy may be able to reverse some aspects of
metabolic syndrome[4].
Further, a low plasma testosterone level appeared to be
associated with endothelial dysfunction in men inde-
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of endogenous testosterone on the endothelium[5]. In
addition, serum endogenous androgen concentrations
were inversely associated with arterial stiffness in men
with type 2 diabetes mellitus[6]. There is an association of
type 2 diabetes with low testosterone values, and there-
fore, the effects of an intervention with testosterone are of
considerable interest. In hypogonadal men, the few stud-
ies on the effects of testosterone treatment on glycemic
control were divergent. One study replacing testosterone
in hypogonadal men with type 2 diabetes found no effect
on glycemic control[7], however another study analyzing
24 hypogonadal men with type 2 diabetes, of which 10
treated with insulin, found that testosterone replacement
therapy improved glycemic control[8] confirming an ear-
lier study[9].
In view of the potential relevance of normalization of
plasma testosterone for glycemic control in type 2 diabe-
tes and for vascular function, we undertook a pilot study
and administered testosterone to men with a diabetic foot
and who were found to have plasma testosterone below
the reference range.
Methods
All patients received information that they received exper-
imental treatment' to which they consented. This pilot
study was approved by the institute's ethical review board.
Written informed consent was obtained from each of the
patients for publication of this Case Report and any
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
Patient # 1. A 48-year-old man, presented with diagnosis:
type 1 diabetes, dry necrosis of tissues in a projection of V
bone of metatarsus (figure 1).
Results of laboratory investigations included hemoglobin
(13.1 g/dL), hematocrit (46.6%), leukocytes (9.7 × 109/
L), HbA1c (7.4%), fibrinogen (6.8 g/L (normal range 2–4
g/L)), antithrombin III activity (87% (normal range 74%–
114%)). Other results of blood chemistry were within
normal limits, except for plasma glucose (14.0 mmol/L).
Endocrinological findings: total testosterone (7.2 nmol/L
(normal range for adult men 12–35 nmol/L)). Bacterio-
logical culture: growth of epidermal staphylococcus in the
wound. Using doppler ultrasound severe stenosis of tibial
arteries in the distal part of the right anticnemion was
found. X-ray examination did not show signs of osteomy-
elitis of foot bones. Tissue oxygen tension (TpO2) was 5
mm Hg. Daily treatment included Cefotaxim 2 g, the
heparin Fraxiparin 0.6 ml, Vessel Due F 0.5 LPE, dressing
of the wound. In addition, one injection of parenteral tes-
tosterone undecanoate (TU) (1000 mg) was adminis-
tered, whereupon plasma levels of total testosterone rose
to 20.3 nmol/L.
Results of investigations 17 days after injection of TU:
decrease of leukocyte count (5.6 × 109/L), plasma glucose
level (6.8 mmol/L), fibrinogen level (5.0 g/L), increased
antithrombin III activity (93%), increase of TpO2 (18 mm
Hg). The wound showed now granulation (figure 2).
Plasma glucose level remained stable within the range of
6–8 mmol/L.
Patient # 2., a 77-year-old man, presented to our depart-
ment with diagnosis: type 2 diabetes, phlegmone of the
right foot, osteomyelitis of the right calcaneus, critical
ischemia of the right leg, coronary heart disease, heart fail-
ure, bilateral hydrothorax requiring continuous drainage
of pleural effusion amounting to more than 2 litres per
day, using permanent vacuum aspiration, renal failure
(figure 3).
Results of laboratory investigations while receiving treat-
ment with Netilmicin (0.4 g daily) and fraxiparin (0.6 ml
daily): hemoglobin (10.4 g/dL), hematocrit (33.1%), leu-
Patient # 1 before administration of testosteroneFigure 1
Patient # 1 before administration of testosterone.
Patient # 1 after administration of testosteroneFigure 2
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2–4 g/L)), antithrombin III activity (74% (normal range
74%–114%)), degree of aggregation – 91.9%, rate of
thrombosis – 58%/min. Other blood chemistry tests were
within normal limits, with exception of plasma glucose
(10 mmol/L). A bacteriological culture revealed bacterial
growth in the wound. TpO2 of the foot was 2 mmHg.
Plasma testosterone levels were below normal (total testo-
sterone 10.5 nmol/L and even more so of bioavailable tes-
tosterone: 2.58 nmol/L.
Results of investigations 25 days after injection of 1000
mg testosterone undecanoate: increase of plasma testo-
sterone to 22.5 nmol/L; stabilization of general condition
of the patient, relief of heart failure symptoms, hydrotho-
rax, decrease of leukocyte level (8.0 × 109/L), plasma glu-
cose level (6.5 mmol/L), decrease of a degree of
aggregation – 23.8% and rate of thrombosis – 23%/min.,
increase of antithrombin III activity (88%), increase of
TpO2 (50 mmHg), increase of the granulation in the
wound and occurrence of border epithelization (figure 4).
Glucose level remained stable within the range of 5–8
mmol/L.
Patient # 3, a 73 year-old man, presented with the diagno-
sis: type 2 diabetes, diabetic foot, neuroischemic form.
Gangrene of the left foot. Atherosclerotic occlusion of
femoropopliteal segment. Critical ischemia of the left
foot. Coronary heart disease. (figure 5).
Laboratory investigations: hemoglobin (12.6 g/L), hema-
tocrit (36.4%), leukocytes (12,9 × 109/L), HbA1c (13.5%),
fibrinogen (6.8 g/L (normal range 2–4 g/L)), anti-
thrombin III activity (63% (normal range 74%–114%)).
Patient # 2 before administration of testosteroneFigure 3
Patient # 2 before administration of testosterone.
Patient # 2 after administration of testosteroneFigure 4
Patient # 2 after administration of testosterone.
Patient # 3 before administration of testosteroneFigure 5
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except for plasma glucose level (12.7 mmol/L). Plasma
total testosterone was 1.9 nmol/L (normal range for adult
men 12–35 nmol/L). Bacteriological culture: growth of
epidermal staphylococcus in the wound. Critical stenosis
of popliteal artery and arteria tibialis posterior was found
by doppler ultrasound of the legs. Tissue oxygen tension
(TpO2) was 28 mm Hg). The patient underwent superfi-
cial femoro-peroneal shunting with autovein and mar-
ginal resection with disarticulation of toes 2–5 of the left
foot. Daily treatment included Cefotaxim 2 g, Metronida-
zole 600 mg, Fraxiparin 0.6 ml, Thrombo ASS 100 mg,
dressing of the wound. The patient also received one injec-
tion of testosterone undecanoate 1000 mg, whereupon
plasma levels of total testosterone had risen to 38 nmol/L
after 14 days.
Test results after 2 months of treatment: decrease of leuko-
cyte level (8,1 × 109/L), plasma glucose level (4.8 mmol/
L), fibrinogen level (5.5 g/L), increase of antithrombin III
activity (80%), increase of TpO2 (37 mm Hg) The wound
showed granulation (figure 6). Glucose levels remained
stable within the range of 4–7 mmol/L.
Discussion
There is an abundance of studies establishing that men
with the metabolic syndrome, cardiovascular disease and
type 2 diabetes have lower-than-normal circulating levels
of testosterone. But, as yet, there is a paucity of studies on
effects of interventions aiming to restore circulating testo-
sterone to normal[8].
In this pilot study we administered testosterone to men
with a diabetic foot who had hypogonadal testosterone
levels. There were remarkable improvements.
It is as yet not possible to provide a plausible explanation
for these beneficial effects. Recent studies have uncovered
a multitude of effects of testosterone in male (patho)phys-
iology which might have played a role.
1) Testosterone has a stimulatory effect on erythropoiesis
occuring within weeks after testosterone administra-
tion[10]. In our patients, indeed, a rise of hemoglobin lev-
els was found
2) There are many studies now establishing a relationship
between low serum testosterone and lower extremity
peripheral artery disease[11] but results of intervention
studies are few. A recent study found a positive effect of
administration of testosterone on vascular function[12]
though most earlier studies have reported an impaired
flow-mediated vasodilatation upon testosterone adminis-
tration to hypogonadal men[13]. In vitro-studies or ani-
mal studies showed that testosterone can exert acute vaso-
relaxing effects via non-genomic mechanisms. These
effects involve primarily the vascular smooth muscle,
without requiring the presence of endothelium, although
an endothelial contribution is apparent in some studies.
To date, the mechanism behind the vasodilatory action of
testosterone is still under debate and might be through
either activation of K (+) channels or blockade of Ca (2+)
channels in vascular muscle cells[14].
To explain the beneficial effects of administration of tes-
tosterone on the diabetic foot, a parallel may be drawn
with erectile dysfunction (ED). ED may originate from
vascular insufficiency and the beneficial effects of phos-
pho-diesterase type 5 (PDE) inhibitors is well docu-
mented. The vaso-relaxation effect of NO on vascular
smooth muscle is mediated by cyclic GMP (cGMP), which
is catabolized by phosphodiesterase (PDE). PDE5 inhibi-
tors, which are used to treat erectile dysfunction, increase
the bioavailability of cGMP, which activates protein
kinase G thereby promoting vasodilatation resulting in
penile erection. It is increasingly clear that testosterone
plays a role in its own right in the vascular physiology of
penile erection promoting NO production[15] and the
combination of PDE5 inhibitors with testosterone has
been very successful in treating erectile dysfunc-
tion[16,17]. In our patients there was an improvement of
Patient # 3 after administration of testosteroneFigure 6
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cular function.
3) Apart from effects on the vascular system, testosterone
may have had anabolic effects on protein synthesis[18]
explaining the beneficial effects of restoring plasma testo-
sterone to the normal range.
4) In animal experimentation androgens at physiological
doses inhibit oxidative-stress-induced platelet aggregation
via its receptor, which is associated with the reduction of
thromboxane A(2) release from platelets[19]. Testoster-
one has also been found to have a positive effect on fibri-
nolysis[20]. In our patients there was a decrease of
fibrinogen and an increase of antithrombin activity upon
testosterone administration.
5) Inflammation is increasingly recognized as an etiolog-
ical factor in cardiovascular disease [21,22] Testosterone
treatment of hypogonadal men shifted the cytokine bal-
ance to a state of reduced inflammation[23]. Dihydrotes-
tosterone positively regulated endothelial function
through the control of the inflammatory response medi-
ated by nuclear factor-kappaB in endothelial cells[24]. In
our study inflammation markers were not studied but
there was reduction in leukocyte counts.
6) The actions of 5alpha-dihydrotestosterone and testo-
sterone were primarily deleterious in cutaneous wound
healing in a series of studies[25]. This suggests that
administration of testosterone might be unfavorable in
this regard.
Our findings are observational and should invite studies
with an appropriate design to explore whether normaliza-
tion of testosterone levels in hypogonadal men with a dia-
betic foot can improve one of the most incapacitating and
potentially lethal complications of diabetes mellitus.
Conclusion
Diabetes mellitus type 2 is very commonly associated with
lower-tan-normal serum testosterone levels. In this study
three men with a diabetic foot and subnormal serum tes-
tosterone, received testosterone treatment. The healing
process of the diabetic foot took a favourable turn. This
observation invites well-designed studies into the possi-
bly favourable effects of restoring testosterone levels to
normal in men suffering from a diabetic foot.
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